標(biāo)題: Titlebook: Atlas of Imaging in Cardio-Oncology; Case-Based Study Gui Richard M. Steingart,Jennifer E. Liu Book 2021 Springer Nature Switzerland AG 202 [打印本頁(yè)] 作者: aspirant 時(shí)間: 2025-3-21 17:53
書目名稱Atlas of Imaging in Cardio-Oncology影響因子(影響力)
書目名稱Atlas of Imaging in Cardio-Oncology影響因子(影響力)學(xué)科排名
書目名稱Atlas of Imaging in Cardio-Oncology網(wǎng)絡(luò)公開度
書目名稱Atlas of Imaging in Cardio-Oncology網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Atlas of Imaging in Cardio-Oncology被引頻次
書目名稱Atlas of Imaging in Cardio-Oncology被引頻次學(xué)科排名
書目名稱Atlas of Imaging in Cardio-Oncology年度引用
書目名稱Atlas of Imaging in Cardio-Oncology年度引用學(xué)科排名
書目名稱Atlas of Imaging in Cardio-Oncology讀者反饋
書目名稱Atlas of Imaging in Cardio-Oncology讀者反饋學(xué)科排名
作者: 修改 時(shí)間: 2025-3-21 20:20
studies presented by practitioners from around the globe to .This atlas provides a practically applicable didatic case-based guide to the use of cardiac imaging in patient care during and after cancer therapy. It features detailed information on a variety of imaging modalities,?including transesopha作者: 嘴唇可修剪 時(shí)間: 2025-3-22 01:56 作者: 事與愿違 時(shí)間: 2025-3-22 08:04 作者: acrobat 時(shí)間: 2025-3-22 12:16
Nicole C. Panarelli,Rhonda K. Yantisses not often afford such a luxury in that most clinical presentations involving ventricular dysfunction have multifactorial determinants. Exploring the entity of stress cardiomyopathy provides a good conceptual framework for the examination of acute ventricular dysfunction in cancer patients.作者: conspicuous 時(shí)間: 2025-3-22 16:13
Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy,nts (axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel) are CD-19-directed. Cardio-oncologists should familiarize themselves with surveillance strategies for cardiovascular events following CAR T-cell therapy, given the risk for de novo arrhythmia and heart failure.作者: originality 時(shí)間: 2025-3-22 20:00 作者: Focus-Words 時(shí)間: 2025-3-23 00:47 作者: 感染 時(shí)間: 2025-3-23 04:43 作者: Biguanides 時(shí)間: 2025-3-23 09:20
https://doi.org/10.1007/978-3-658-36308-6instay of treatment involving cessation of the ICI and the administration of corticosteroids. The three cases presented below will highlight differences in clinical presentations, diagnostic tests, and treatments followed by an in-depth discussion of these differences.作者: Protein 時(shí)間: 2025-3-23 10:41
Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis,instay of treatment involving cessation of the ICI and the administration of corticosteroids. The three cases presented below will highlight differences in clinical presentations, diagnostic tests, and treatments followed by an in-depth discussion of these differences.作者: Cardioversion 時(shí)間: 2025-3-23 16:27 作者: GLOOM 時(shí)間: 2025-3-23 21:45
Cardiovascular Toxicities of Proteasome Inhibitors, particularly deleterious to patients with MM who have a high incidence of underlying cardiovascular comorbidities.?This chapter will review the cardiovascular toxicities associated with PIs and illustrate the utility of imaging in diagnosing and managing these complications.作者: menopause 時(shí)間: 2025-3-23 23:19 作者: 羊欄 時(shí)間: 2025-3-24 05:42
https://doi.org/10.1007/978-3-031-07574-2 to treat certain lymphomas and leukemias. The indications for CAR T-cells are expected to continue expanding, but presently all?four FDA-approved agents (axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel) are CD-19-directed. Cardio-oncologists should fam作者: exacerbate 時(shí)間: 2025-3-24 08:55
https://doi.org/10.1007/978-3-642-11587-5n substantial improvement in patient outcomes.?Proteasome inhibitors (PI) are one such class of therapy and are now included in first-line regimens for MM. However, PIs are associated with important cardiotoxicities including?heart failure, arrhythmias, and thromboembolism. These adverse effects are作者: 樂章 時(shí)間: 2025-3-24 12:35
https://doi.org/10.1007/978-3-642-71745-1bone marrow and stem cell transplants, and radiation therapy. Each of these therapeutic categories confers substantial benefit and some degree of cardiovascular risk. Careful attention is warranted especially in patients with known heart disease.作者: Exhilarate 時(shí)間: 2025-3-24 17:45 作者: Diatribe 時(shí)間: 2025-3-24 20:36
https://doi.org/10.1007/978-3-7091-5463-2 the constellation of flushing, diarrhea, and bronchospasm known as carcinoid syndrome. These substances cause plaque-like deposits to form on endocardial surfaces resulting in predominantly right-sided valve abnormalities. Advances in diagnostic imaging, medical therapies, and interventional techni作者: pulse-pressure 時(shí)間: 2025-3-24 23:26
Nicole C. Panarelli,Rhonda K. Yantissompartmentalize ventricular dysfunction into distinct categories as an aid in the understanding of the disease. But the practice of cardio-oncology does not often afford such a luxury in that most clinical presentations involving ventricular dysfunction have multifactorial determinants. Exploring th作者: 骨 時(shí)間: 2025-3-25 06:57 作者: Perceive 時(shí)間: 2025-3-25 10:51 作者: 發(fā)芽 時(shí)間: 2025-3-25 12:13
Peter Heutink,Kevin Menden,Anupriya DalmiaThe understanding of the role of dysregulated tyrosine kinases in cancer has produced a literal explosion in approaches to cancer treatment.作者: 波動(dòng) 時(shí)間: 2025-3-25 19:35 作者: perpetual 時(shí)間: 2025-3-25 20:36
Claudia Manzoni,Raffaele FerrariHistorically, most of the attention in terms of cardiovascular diseases among cancer patients has been directed towards cardiac dysfunction.作者: gusher 時(shí)間: 2025-3-26 02:34
Peter Heutink,Kevin Menden,Anupriya DalmiaAn older man with chest pain while receiving dasatinib and ruxolitinib.作者: 昏暗 時(shí)間: 2025-3-26 07:18
https://doi.org/10.1007/978-3-642-11587-5A 41-year-old woman was diagnosed with CML and treated in the first-line setting with dasatinib, a second-generation BCR-ABL TKI. After 2?years of treatment, she achieved a major molecular response but reported new dyspnea on exertion.作者: EXCEL 時(shí)間: 2025-3-26 11:51 作者: 物質(zhì) 時(shí)間: 2025-3-26 15:27 作者: 蛛絲 時(shí)間: 2025-3-26 18:02
https://doi.org/10.1007/978-3-642-11587-5Cardiac risk assessment is a standard component of the pre-hematopoietic stem cell transplantation (HCT) screening, which considers performance status, left ventricular ejection fraction (LVEF), pulmonary function tests, and existing cardiovascular (CV) comorbidities.作者: 喧鬧 時(shí)間: 2025-3-26 21:31
Frost, Drought, and Heat ResistanceNearly 17 million people in the U.S. are living with cancer [.]—survivorship has markedly improved in the past decades, highlighting the importance of effective strategies to surveil cancer complications in this population.作者: 萬(wàn)靈丹 時(shí)間: 2025-3-27 02:57 作者: 青石板 時(shí)間: 2025-3-27 05:54 作者: alliance 時(shí)間: 2025-3-27 10:50
Anthracycline/Trastuzumab Cardiac Toxicity,Anthracycline and Trastuzumab are the two most common cancer agents associated with chemotherapy-related cardiac dysfunction (CTRCD). This chapters aims to discuss the latest definitions of CTRCD, the mechanisms and treatment of CTRCD, as well as the role of multi-modal cardiac imaging in Anthracycline and trastuzuamb cardiotoxicity.作者: KEGEL 時(shí)間: 2025-3-27 16:50 作者: visceral-fat 時(shí)間: 2025-3-27 20:13 作者: browbeat 時(shí)間: 2025-3-27 22:33 作者: 善辯 時(shí)間: 2025-3-28 02:19
Vascular Toxicity of Tyrosine Kinase Inhibitors: Coronary Artery Disease,An older man with chest pain while receiving dasatinib and ruxolitinib.作者: Meager 時(shí)間: 2025-3-28 08:42
Vascular Toxicity of Tyrosine Kinase Inhibitors: Pulmonary Hypertension,A 41-year-old woman was diagnosed with CML and treated in the first-line setting with dasatinib, a second-generation BCR-ABL TKI. After 2?years of treatment, she achieved a major molecular response but reported new dyspnea on exertion.作者: 配置 時(shí)間: 2025-3-28 11:50 作者: mastopexy 時(shí)間: 2025-3-28 16:39
Cisplatin and Carboplatin,Platinum-based agents belong to alkylating antineoplastic agents. They are the backbone of most chemotherapeutic regimens in many cancer types, including testicular cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, bladder cancer, and head and neck cancer.作者: 擁擠前 時(shí)間: 2025-3-28 20:08 作者: stress-test 時(shí)間: 2025-3-29 01:31 作者: 命令變成大炮 時(shí)間: 2025-3-29 03:23 作者: GLADE 時(shí)間: 2025-3-29 07:19
The Role of Myocardial Perfusion Imaging in Cardiac Clearance of Cancer Patients,bone marrow and stem cell transplants, and radiation therapy. Each of these therapeutic categories confers substantial benefit and some degree of cardiovascular risk. Careful attention is warranted especially in patients with known heart disease.作者: Obstacle 時(shí)間: 2025-3-29 11:37
Perioperative Management of the Cancer Patient,ncer patients incur additional risks related to their malignancies and to their cancer therapies. These unique features carry over into the postoperative period as well and decision-making in the perioperative period can be complex. This chapter will illustrate some of the key issues in treating?the perioperative cancer patient.作者: Campaign 時(shí)間: 2025-3-29 17:16
Richard M. Steingart,Jennifer E. LiuProvides a number of real world case-based scenarios to reveal the clinical subtlety of imaging cardio-oncology patients.Collection of case studies presented by practitioners from around the globe to 作者: Laconic 時(shí)間: 2025-3-29 21:48 作者: MAG 時(shí)間: 2025-3-30 00:09 作者: Analogy 時(shí)間: 2025-3-30 05:12 作者: degradation 時(shí)間: 2025-3-30 08:47 作者: 編輯才信任 時(shí)間: 2025-3-30 14:46
978-3-030-71000-2Springer Nature Switzerland AG 2021作者: 好開玩笑 時(shí)間: 2025-3-30 18:27
to develop a deep understanding of how to utilise a variety of imaging modalities used in cardio-oncology in a range of scenarios. It provides a critical and timely resource for the trainee and experienced cardiologist, oncologist and radiologist..978-3-030-71000-2978-3-030-70998-3作者: 歡笑 時(shí)間: 2025-3-31 00:18
Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis,ite the presumed low incidence of myocarditis, increasing use and the expansion of ICIs for treating different malignancies have?led to an increase in the number of cases being seen in academic centers and the community. Any cardio-oncology practice must be equipped to recognize and treat this poten作者: HAIRY 時(shí)間: 2025-3-31 02:42 作者: Subjugate 時(shí)間: 2025-3-31 07:27
Cardiovascular Toxicities of Proteasome Inhibitors,n substantial improvement in patient outcomes.?Proteasome inhibitors (PI) are one such class of therapy and are now included in first-line regimens for MM. However, PIs are associated with important cardiotoxicities including?heart failure, arrhythmias, and thromboembolism. These adverse effects are作者: 粗魯性質(zhì) 時(shí)間: 2025-3-31 12:51
The Role of Myocardial Perfusion Imaging in Cardiac Clearance of Cancer Patients,bone marrow and stem cell transplants, and radiation therapy. Each of these therapeutic categories confers substantial benefit and some degree of cardiovascular risk. Careful attention is warranted especially in patients with known heart disease.
